respiratori
virus
respons
larg
proport
acut
respiratori
ill
adult
well
children
associ
huge
socioeconom
burden
worldwid
develop
accur
pointofcar
test
poct
respiratori
virus
list
prioriti
world
health
organis
replac
current
paradigm
empir
antimicrobi
use
direct
use
list
goal
movement
reduct
antimicrobi
resist
poct
respiratori
virus
previous
limit
poor
sensit
antigen
detect
base
test
limit
rang
detect
virus
highli
accur
molecular
platform
abl
test
comprehens
rang
virus
oper
nonlaboratori
staff
gener
result
approxim
h
make
potenti
deploy
poct
potenti
clinic
benefit
poc
test
respiratori
virus
adult
includ
reduct
unnecessari
antibiot
use
improv
antivir
prescrib
influenza
rationalis
isol
facil
review
burden
diseas
current
avail
molecular
platform
potenti
poct
use
exist
evid
clinic
econom
benefit
test
respiratori
virus
adult
summari
respiratori
virus
respons
larg
proport
acut
respiratori
ill
adult
well
children
associ
huge
socioeconom
burden
worldwid
develop
accur
pointofcar
test
poct
respiratori
virus
list
prioriti
world
health
organis
replac
current
paradigm
empir
antimicrobi
use
direct
use
list
goal
movement
reduct
antimicrobi
resist
poct
respiratori
virus
previous
limit
poor
sensit
antigen
detect
base
test
limit
rang
detect
virus
highli
accur
molecular
platform
abl
test
comprehens
rang
virus
oper
nonlaboratori
staff
gener
result
approxim
h
make
potenti
deploy
poct
potenti
clinic
benefit
poc
test
respiratori
virus
adult
includ
reduct
unnecessari
antibiot
use
improv
antivir
prescrib
influenza
rationalis
isol
facil
review
burden
diseas
current
avail
molecular
platform
potenti
poct
use
exist
evid
clinic
econom
benefit
test
respiratori
virus
adult
british
infect
associ
publish
elsevi
ltd
right
reserv
acut
respiratori
tract
infect
respons
estim
million
death
year
third
common
caus
death
worldwid
although
bacteria
previous
consid
princip
aetiolog
agent
sever
respiratori
infect
global
import
respiratori
virus
age
group
increasingli
recognis
recent
year
diagnost
technolog
respiratori
viru
detect
evolv
rapidli
last
two
decad
viral
cultur
immunofluoresc
current
standard
molecular
detect
polymeras
chain
reaction
pcr
review
focus
current
avail
molecular
diagnost
platform
respiratori
viru
detect
potenti
use
pointofcar
test
poct
explor
current
landscap
poct
adult
improv
sensit
diagnost
test
respiratori
virus
widespread
use
nucleic
amplif
techniqu
pcr
help
accur
defin
burden
viral
diseas
past
two
decad
children
respiratori
virus
detect
molecular
diagnost
techniqu
case
commun
acquir
pneumonia
cap
infant
bronchiol
approxim
asthma
exacerb
adult
approxim
cap
case
asthma
exacerb
chronic
obstruct
pulmonari
diseas
exacerb
associ
respiratori
viru
detect
hospitalis
adult
acut
respiratori
ill
virus
commonli
detect
pathogen
detect
around
bacteri
detect
much
less
frequent
although
antibiot
use
almost
univers
furthermor
preced
viral
infect
thought
key
predispos
event
secondari
bacteri
infect
lung
site
respiratori
tract
respiratori
virus
includ
influenza
also
implic
precipit
nonrespiratori
ill
myocardi
infarct
venou
thromboembol
stroke
loss
diabet
control
infect
respiratori
virus
frequent
event
age
group
result
enorm
burden
health
system
well
econom
cost
direct
medic
expens
indirect
product
loss
direct
medic
expens
includ
outpati
clinic
visit
emerg
depart
visit
hospitalis
treatment
cost
includ
overthecount
medic
drug
prescript
indirect
product
loss
includ
miss
workday
adult
patient
caregiv
europ
direct
cost
attribut
pneumonia
estim
approxim
billion
annual
indirect
cost
lost
work
day
billion
base
popul
size
season
influenza
epidem
result
averag
lifeyear
lost
million
hospit
day
million
outpati
visit
usa
direct
medic
cost
averag
us
billion
annual
project
lost
earn
due
ill
loss
life
amount
us
billion
annual
total
econom
burden
annual
influenza
epidem
use
project
statist
life
valu
amount
us
billion
common
cold
also
caus
signific
econom
burden
usbas
studi
estim
noninfluenza
viral
respiratori
tract
ill
mostli
common
cold
cost
around
us
billion
influenza
viru
caus
season
epidem
lead
excess
hospitalis
death
mainli
elderli
patient
comorbid
caus
sever
ill
million
peopl
around
half
million
death
per
year
worldwid
annual
season
influenza
vaccin
recommend
risk
group
howev
vaccin
uptak
suboptim
high
qualiti
evid
signific
protect
elderli
lack
rate
hospitalis
adult
influenza
estim
per
overal
may
high
per
year
old
adult
hospitalis
laboratori
confirm
influenza
admit
critic
care
unit
die
hospit
outcom
predict
comorbid
note
addit
acut
respiratori
present
influenza
may
precipit
decompens
cardiovascular
diseas
myocardi
infarct
collaps
diabet
emerg
mani
hospitalis
case
influenza
like
remain
undiagnos
recent
canadian
studi
estim
around
emerg
depart
visit
due
influenza
viru
infect
correctli
attribut
influenza
like
therefor
burden
influenza
econom
impact
underestim
rsv
principl
caus
bronchiol
infant
increasingli
recognis
major
caus
sever
respiratori
ill
adult
studi
suggest
diseas
burden
similar
influenza
rsv
affect
age
group
studi
hospitalis
children
adult
calcul
disabl
adjust
life
year
dali
conclud
influenza
rsv
consist
greatest
caus
diseas
across
age
group
adult
high
risk
sever
rsv
diseas
includ
frail
elderli
chronic
cardiorespiratori
diseas
immunocompromis
mortal
rate
rsv
infect
adult
elderli
similar
influenza
may
reach
heavili
immunocompromis
contrast
neglig
rsvrelat
mortal
infect
children
picornavirus
respons
major
common
cold
adult
typic
suffer
two
four
symptomat
episod
per
year
also
respons
major
exacerb
asthma
adult
signific
proport
exacerb
copd
common
cold
caus
estim
million
lost
workday
per
year
us
estim
annual
cost
around
us
million
rhinovirusrel
asthma
exacerb
adenoviru
infect
common
caus
mild
acut
respiratori
ill
children
also
caus
epidem
among
adult
militari
recruit
caus
seriou
infect
immunocompromis
occasion
immunocompet
adult
clinic
impact
human
coronavirus
infect
recent
explor
earli
data
suggest
preval
adult
hospitalis
acut
respiratori
ill
us
multicentr
studi
show
preval
human
metapneumoviru
hmpv
infect
hospitalis
adult
respiratori
symptom
patient
similar
clinic
characterist
infect
rsv
infect
increas
age
risk
factor
emerg
depart
visit
hospitalis
parainfluenza
virus
seem
less
import
adult
compar
paediatr
popul
howev
caus
influenzalik
ill
adult
detect
adult
hospitalis
acut
respiratori
ill
low
frequenc
diagnost
test
respiratori
virus
laboratori
pcr
nucleic
acid
amplif
techniqu
pcr
larg
supersed
cell
cultur
direct
fluoresc
antibodi
test
method
choic
routin
diagnost
test
respiratori
virus
due
superior
diagnost
accuraci
faster
turnaround
time
pcr
highli
sensit
specif
gener
turnaround
time
least
h
requir
specialist
laboratori
facil
expertis
rapid
antigen
detect
test
respiratori
virus
sever
commerci
avail
fda
approv
ce
mark
rapid
diagnost
test
respiratori
virus
includ
influenza
rsv
use
antigen
detect
either
immunechromatograph
assay
immunofluoresc
time
result
gener
around
fifteen
minut
easi
use
requir
laboratori
support
gener
involv
visual
inspect
test
line
addit
control
line
unfortun
clinic
util
rapid
antigen
base
detect
respiratori
virus
limit
unaccept
poor
sensit
especi
adult
around
influenza
lower
rsv
mean
use
rule
infect
sofia
fluoresc
immunoassay
analyz
quidel
san
diego
ca
usa
benchtop
analys
combin
later
flow
immunofluorescencebas
antigen
detect
test
kit
optic
sensor
provid
result
around
min
test
kit
avail
influenza
rsv
fda
approv
ce
mark
sensit
detect
influenza
around
compar
pcr
may
higher
rapid
antigen
test
although
evalu
adult
children
sensit
detect
rsv
around
compar
pcr
would
expect
lower
adult
maripoc
arcdia
laboratori
turku
finland
ce
mark
multianalyt
immunofluorescencebas
antigen
detect
platform
simultan
detect
respiratori
virus
influenza
b
rsv
adenoviru
hmpv
parainfluenza
type
addit
streptococcu
pneumonia
evalu
adult
compar
rtpct
children
acut
respiratori
ill
diagnost
accuraci
gener
moder
although
sensit
low
viral
target
molecular
platform
pointofcar
test
potenti
aler
influenza
b
aler
san
diego
ca
usa
fda
approv
ce
mark
isotherm
nucleic
acid
amplificationbas
system
use
fluorescencebas
molecular
signal
detect
influenza
b
result
gener
within
min
around
min
hand
time
test
kit
analys
specif
design
use
nonlaboratori
clinic
staff
acut
care
environ
molecular
platform
fda
approv
specif
poct
studi
examin
diagnost
accuraci
involv
respiratori
specimen
symptomat
patient
children
adult
sensit
specif
aler
influenza
b
assay
influenza
influenza
b
compar
viral
cultur
pcr
howev
swiss
studi
particip
broadli
twothird
children
onethird
adult
show
lower
pool
influenza
b
sensit
mostli
influenza
rather
b
compar
pcr
anoth
studi
use
sampl
predominantli
adult
show
even
lower
sensit
influenza
high
specif
demonstr
simplic
use
fast
turnaround
time
make
aler
influenza
b
test
excit
prospect
pointofcar
use
howev
clinic
trial
evalu
clinic
health
econom
outcom
lower
sensit
adult
influenza
limit
rang
pathogen
detect
limit
use
filmarray
respiratori
panel
biofir
diagnost
salt
lake
citi
ut
usa
fda
approv
ce
mark
platform
use
nest
realtim
pcr
detect
respiratori
pathogen
viral
target
bacteria
filmarray
requir
min
hand
time
produc
test
result
one
hour
sever
publish
studi
evalu
easeofus
turnaround
time
system
compar
diagnost
accuraci
laboratori
pcr
studi
shown
superior
filmarray
system
term
easeofus
turnaround
time
compar
laboratori
pcr
sensit
specif
compar
laboratori
pcr
confirmatori
cell
cultur
sequenc
excel
initi
pool
sensit
viral
target
around
e
princip
due
poor
sensit
adenoviru
detect
howev
follow
improv
adenoviru
assay
risen
notabl
studi
conduct
within
laboratori
rather
pointofcar
larg
proport
studi
conduct
use
sampl
children
rather
adult
notabl
limit
system
workflow
singl
specimen
test
one
time
analys
singl
studi
examin
clinic
outcom
children
hospitalis
acut
respiratori
ill
test
filmarray
respiratori
panel
compar
standard
laboratori
pcr
randomis
control
trial
examin
outcom
pre
post
intervent
filmarray
respiratori
panel
use
poct
hous
within
exist
laboratori
studi
demonstr
patient
test
filmarray
test
result
avail
clinician
mean
time
h
versu
around
h
standard
laboratori
pcr
durat
antibiot
shorter
test
filmarray
although
depend
receiv
test
result
within
h
durat
inpati
stay
time
isol
facil
shorter
test
filmarray
result
posit
virus
trial
adult
randomis
control
trial
date
examin
potenti
clinic
benefit
use
system
poct
xpert
flu
cepheid
sunnyval
ca
usa
realtim
pcr
test
cartridg
fda
approv
ce
mark
test
use
integr
autom
genexpert
platform
detect
influenza
b
turnaround
time
min
report
hand
time
min
modular
multipl
port
system
allow
ondemand
randomaccess
test
test
run
simultan
depend
number
port
test
unit
system
evalu
prospect
trial
use
sampl
adult
acut
respiratori
ill
emerg
depart
group
sensit
detect
influenza
e
specif
ci
compar
laboratori
pcr
although
compar
easi
use
test
current
publish
trial
evalu
use
pointofcar
test
evalu
potenti
clinic
health
econom
benefit
use
emerg
depart
combin
xpert
flursv
cartridg
evalu
retrospect
studi
use
adult
paediatr
sampl
demonstr
sensit
influenza
influenza
b
rsv
specif
three
virus
compar
laboratori
pcr
uk
depart
health
commiss
report
uk
patholog
servic
note
import
develop
clinic
relev
pointofcar
diagnost
test
reduc
turnaround
time
improv
patient
pathway
despit
poct
infecti
diseas
uk
global
advanc
far
beyond
dipstick
test
urinari
tract
infect
vitro
diagnost
test
infect
remain
confin
larg
centralis
laboratori
associ
slow
turnaround
time
mean
result
avail
clinician
mani
hour
sever
day
patient
present
long
antimicrobi
decis
made
perpetu
current
paradigm
empir
antimicrobi
use
rather
pathogen
direct
use
infecti
diseas
societi
america
polici
paper
better
test
better
care
improv
diagnost
infecti
diseas
acknowledg
ongo
cultur
empir
antimicrobi
use
unmet
need
rapid
accur
test
infecti
diseas
allow
appropri
pathogen
direct
therapi
wold
econom
forum
state
antimicrobi
resist
arguabl
greatest
threat
global
human
health
current
high
profil
initi
combat
resist
focus
attent
antimicrobi
stewardship
seek
preserv
exist
antimicrobi
agent
slow
develop
resist
one
strategi
achiev
goal
develop
rapid
diagnost
test
biomark
ensur
appropri
use
antimicrobi
antimicrobi
use
pathogen
direct
rather
empir
use
clear
evid
benefit
addit
increas
recognit
huge
global
burden
respiratori
virus
led
creation
global
battl
respiratori
virus
initi
brave
initi
aim
improv
research
strategi
prevent
diagnos
manag
respiratori
viru
infect
prioriti
area
includ
improv
diagnost
test
respiratori
virus
includ
creation
use
cheap
accur
easi
use
poct
current
cultur
empir
antimicrobi
use
patient
suspect
infect
longer
consid
sustain
due
emerg
prolifer
antibiot
resist
antibiot
use
hospitalis
patient
acut
respiratori
ill
near
univers
despit
predomin
virus
low
frequenc
detect
bacteria
much
patient
group
fig
show
antibiot
use
detect
pathogen
larg
studi
hospitalis
adult
uk
furthermor
patient
acut
respiratori
ill
syndrom
known
princip
viral
induc
exacerb
asthma
acut
bronchiti
often
treat
antibiot
despit
lack
evid
benefit
case
asthma
nation
guidelin
discourag
use
studi
uk
referenc
almost
patient
hospitalis
exacerb
asthma
receiv
least
one
dose
antibiot
whilst
hospit
use
respiratori
viru
poct
could
potenti
reduc
unnecessari
antibiot
use
patient
acut
respiratori
ill
especi
condit
known
princip
viral
antibiot
use
shown
benefit
demonstr
clinician
patient
ill
fever
explain
presenc
viru
patient
uncompl
influenzalik
ill
caus
respiratori
virus
includ
influenza
often
treat
antibiot
due
diagnost
confus
bacteri
infect
patient
earli
detect
respiratori
viru
absenc
evid
concomit
bacteri
infect
may
prevent
unnecessari
antibiot
use
evid
base
respiratori
viru
test
reduc
unnecessari
antibiot
use
limit
mainli
consist
trial
use
rapid
antigen
base
test
influenza
larg
randomis
control
trial
evalu
clinic
health
econom
benefit
rapid
antigen
test
influenza
hospitalis
adult
demonstr
improv
antibiot
use
clinic
health
econom
benefit
test
rapid
antigen
test
compar
laboratori
test
small
nonrandomis
studi
hospitalis
adult
rapid
diagnost
test
influenza
use
antigen
detect
demonstr
small
reduct
antibiot
use
vs
increas
advers
event
antibiot
withheld
studi
children
includ
sever
small
randomis
control
trial
evalu
impact
routin
rapid
antigen
test
influenza
antibiot
use
inconsist
result
molecular
test
evid
base
even
limit
trial
use
molecular
test
platform
within
laboratori
rather
poct
associ
prolong
turnaround
time
impact
respiratori
viru
test
adult
outpati
acut
respiratori
ill
assess
small
randomis
control
trial
use
laboratorybas
pcr
result
avail
next
day
randomis
viral
pcr
test
even
delay
antibiot
prescrib
significantli
reduc
compar
treat
standard
care
vs
note
filmarray
respiratori
platform
clinic
evalu
singl
centr
paediatr
studi
platform
use
poct
hous
within
central
laboratori
although
randomis
control
trial
demonstr
reduct
antibiot
use
test
posit
virus
filmarray
versu
standard
laboratori
pcr
although
result
avail
within
h
underscor
import
rapid
result
suggest
possibl
reduct
platform
use
poct
recent
cochran
review
evalu
use
rapid
viral
diagnost
acut
febril
respiratori
ill
children
emerg
depart
conclud
current
insuffici
evid
support
rapid
viral
test
reduc
antibiot
use
set
author
suggest
adequ
power
trial
antibiot
use
primari
outcom
measur
direct
antivir
agent
use
influenza
neuraminidas
inhibitor
nai
oseltamivir
zanamivir
licens
antivir
treatment
prevent
influenza
recommend
uk
public
health
england
treatment
hospitalis
adult
suspect
confin
influenza
b
although
controversi
regard
evid
efficaci
origin
pharma
sponsor
trial
larg
bodi
evid
observ
studi
suggest
signific
reduct
mortal
hospitalis
adult
confirm
influenza
although
degre
benefit
nai
probabl
greatest
start
h
symptom
onset
evid
adult
suggest
ongo
benefit
start
beyond
time
day
symptom
particularli
pertin
patient
infect
influenza
often
present
hospit
h
symptom
durat
current
uk
practis
patient
suspect
influenza
gener
treat
empir
nai
whilst
await
result
laboratori
pcr
test
strategi
lead
unnecessari
nai
exposur
associ
risk
side
effect
patient
subsequ
found
influenza
follow
recent
public
independ
metaanalysi
oseltamivir
trial
editori
letter
publish
lancet
suggest
view
modest
efficaci
moder
risk
nausea
vomit
oseltamivir
administr
drug
ideal
direct
use
diagnost
test
rather
use
empir
use
molecular
pointofcar
test
potenti
allow
implement
direct
rather
empir
nai
treatment
thu
maximis
clinic
benefit
influenza
infect
minimis
unnecessari
antivir
exposur
drug
relat
advers
event
without
note
sever
studi
children
singl
studi
adult
suggest
improv
use
nai
use
rapid
antigen
test
influenza
versu
routin
clinic
care
although
studi
evalu
molecular
platform
poct
outcom
measur
addit
nai
sever
promis
novel
repurpos
antiinfluenza
agent
current
late
stage
clinic
develop
includ
nitazoxanid
favipiravir
monoclon
antibodi
current
specif
antivir
agent
licens
rsv
infect
broad
spectrum
antivir
agent
ribavirin
sometim
use
immunocompromis
adult
sever
rsv
infect
use
limit
safeti
concern
difficulti
administ
nebulis
solut
randomis
control
trial
evalu
efficaci
sever
small
molecul
antirsv
agent
late
stage
clinic
develop
includ
gilead
rsv
fusion
protein
inhibitor
demonstr
reduct
symptom
viral
load
challeng
studi
healthi
adult
current
triall
hospitalis
adult
current
specif
antivir
agent
licens
prevent
treatment
rhinoviru
infect
rhinoviru
capsid
bind
agent
pleconaril
show
promis
clinic
trial
natur
occur
cold
reject
us
food
drug
administr
due
rel
high
frequenc
side
effect
drug
interact
concern
resist
phase
trial
human
rhinoviru
capsid
binder
vapendavir
current
underway
adult
asthmat
natur
acquir
rhinoviru
infect
singl
centr
randomis
control
trial
inhal
beta
interferon
demonstr
reduc
sever
rhinoviru
induc
asthma
exacerb
sever
asthmat
larger
confirmatori
trial
ongo
promis
candid
antivir
agent
late
stage
develop
list
tabl
respiratori
virus
known
highli
infecti
caus
nosocomi
outbreak
test
isol
suspect
case
central
tenet
infect
control
practic
hospit
current
case
isol
base
clinic
suspicion
laboratori
test
provid
definit
result
h
lead
patient
without
singl
centr
nonrandomis
paediatr
studi
uk
suggest
signific
improv
isol
facil
use
patient
flow
rapid
antigen
base
poct
rsv
winter
month
previous
mention
nonrandomis
pre
post
intervent
paediatr
studi
use
filmarray
respiratori
panel
poct
demonstr
reduct
time
spent
isol
facil
patient
test
poct
versu
standard
laboratori
pcr
test
sever
studi
evalu
use
antigen
detect
base
poct
influenza
children
shown
decreas
number
investig
perform
influenza
posit
patient
compar
test
standard
care
one
also
suggest
reduct
durat
hospitalis
test
posit
influenza
previous
mention
studi
use
filmarray
children
potenti
clinic
benefit
list
could
translat
overal
econom
benefit
health
care
organis
studi
use
decis
analyt
model
ascertain
cost
effect
test
strategi
children
present
emerg
depart
influenzalik
ill
suggest
rapid
pcr
use
filmarray
respiratori
panel
superior
standard
laboratori
pcr
rapid
antigen
test
howev
increment
cost
per
qali
high
mani
question
assumpt
effect
diagnos
respiratori
viru
infect
investig
antibiot
antivir
use
made
anoth
studi
use
health
econom
model
evalu
cost
effect
pcr
base
rapid
diagnost
cepheid
xpert
flu
assay
diagnosi
influenza
high
risk
adult
present
emerg
depart
conclud
pcr
base
rapid
test
cost
effect
strategi
although
depend
preval
influenza
base
strong
assumpt
antivir
use
efficaci
potenti
benefit
poc
test
respiratori
virus
adult
list
tabl
current
global
prioriti
replac
empir
antimicrobi
use
pathogen
direct
therapi
help
combat
resist
coupl
recent
develop
rapid
accur
easytous
molecular
test
platform
respiratori
virus
set
scene
roll
pointofcar
test
strategi
patient
present
acut
respiratori
ill
potenti
benefit
strategi
includ
reduct
unnecessari
antibiot
use
improv
use
direct
antivir
therapi
influenza
improv
use
isol
facil
secondari
care
reduct
number
investig
perform
reduct
durat
hospitalis
situat
effect
could
associ
overal
health
econom
benefit
substanti
evid
gap
high
qualiti
randomis
control
trial
evalu
molecular
poct
adult
use
clinic
relev
outcom
antibiot
use
direct
antivir
use
infect
control
facil
use
urgent
need
addit
exist
agent
activ
influenza
may
soon
also
avail
rang
clinic
effect
antivir
agent
activ
respiratori
virus
rsv
rhinoviru
agent
utilis
effect
especi
hospitalis
patient
sever
diseas
routin
earli
test
presenc
virus
molecular
poct
necessari
allow
target
treatment
njb
hf
twc
involv
design
literatur
search
write
manuscript
includ
final
version
submit
none
none
declar
author
